Fierce Pharma May 3, 2024
Japan’s Ono Pharmaceutical will buy kinase inhibitor expert Deciphera for $2.4 billion. Novartis invests further in radiopharmaceuticals with two deals. WuXi Biologics has withdrawn from the 2024 BIO International Convention as the U.S. grows hostile against certain Chinese biotech companies. And more.
1. Japan’s Ono pays $2.4B for Qinlock maker Deciphera as biotech readies another approval run
Ono Pharmaceutical, which sells the PD-1 inhibitor Opdivo in Japan, is buying Deciphera Pharmaceuticals for $2.4 billion. Besides the FDA-approved gastrointestinal stromal tumor drug Qinlock, Deciphera comes with a kinase inhibitor discovery platform. Ono also expects the acquisition to accelerate its business development in the U.S. and Europe, CEO Gyo Sagara said.
2. Novartis pays PeptiDream $180M as radiopharma big bang continues
...Today's Sponsors
Today's Sponsor